A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- To assess 365 days mortality of OHI+ and OHI- patients
研究概览
简要总结
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) > 3,900 U/mL and ferritin >1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
详细描述
The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with hematologic malignancies
- •At least 18 years old
排除标准
- •Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)
结局指标
主要结局
To assess 365 days mortality of OHI+ and OHI- patients
时间窗: Mortality rate one year from OHI assessment
The investigators will use Kaplan-Meier curves to compare survival between OHI+ and OHI- patients
次要结局
- To determine the incidence of OHI+ patients in our cohort(The investigators will assess the incidence after three years of enrollment)